Clinic
East Tennessee Recovery, PLLC
East Tennessee Recovery, PLLC was paid $28.28M by Medicaid between Jan 2018 and Dec 2024, across 79 billing codes. Its largest line is G9012, Other specified case management service not elsewhere classified — 23% of everything it billed.
33Billing provider infoEAST TENNESSEE RECOVERY, PLLC
JOHNSON CITY, TN 37601
JOHNSON CITY, TN 37601
33aNPI1114462215assigned 12/27/2016
33bProvider typeSubstance Use Disorder Rehabilitation Clinic/Center
28Total paid$28.28M
24GClaims625,784
24DCodes billed79
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Substance Use Disorder Rehabilitation Clinic/Center providers in Tennessee
Rank by total paid#1 of 30
Median peer was paid$1.03M
This provider vs. median27×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,321 | $1.63M | |
| 2019 | 173,064 | $4.56M | |
| 2020 | 143,413 | $4.11M | |
| 2021 | 78,821 | $3.29M | |
| 2022 | 54,545 | $3.45M | |
| 2023 | 62,512 | $5.40M | |
| 2024incomplete | 70,108 | $5.84M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G9012 | Other specified case management service not elsewhere classified | 23% | 37,077 | 29,914 | $6.62M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 17% | 44,217 | 24,915 | $4.93M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 15% | 79,846 | 41,672 | $4.24M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 9.0% | 66,127 | 33,235 | $2.53M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 5.4% | 42,246 | 30,141 | $1.53M |
| H0016 | Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) | 4.4% | 8,070 | 4,953 | $1.26M |
| H2010 | Comprehensive medication services, per 15 minutes | 3.6% | 7,235 | 3,187 | $1.02M |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | 2.8% | 5,321 | 2,618 | $802K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.2% | 15,101 | 10,190 | $612K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.6% | 38,581 | 25,330 | $445K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.4% | 3,884 | 1,900 | $389K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 2,979 | 1,744 | $254K |
67 more codes
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 8,375 | $227K |
| H0006 | Alcohol and/or drug services; case management | <1% | 2,274 | $222K |
| H0049 | Alcohol and/or drug screening | <1% | 7,213 | $137K |
| 80346 | <1% | 8,113 | $135K | |
| 80356 | <1% | 7,882 | $131K | |
| 99484 | <1% | 10,473 | $124K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,221 | $124K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,626 | $122K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 8,069 | $109K |
| 80355 | <1% | 7,912 | $105K | |
| 80323 | <1% | 7,760 | $101K | |
| 80363 | <1% | 7,293 | $99K | |
| 99406 | <1% | 16,278 | $96K | |
| 80348 | <1% | 8,730 | $91K | |
| 80325 | <1% | 7,081 | $90K | |
| 80359 | <1% | 7,864 | $83K | |
| 80349 | <1% | 7,876 | $82K | |
| 80371 | <1% | 7,792 | $82K | |
| 80350 | <1% | 7,754 | $82K | |
| 80354 | <1% | 7,689 | $81K | |
| 80372 | <1% | 7,685 | $81K | |
| 80373 | <1% | 7,686 | $81K | |
| 80367 | <1% | 7,666 | $81K | |
| 80365 | <1% | 7,607 | $80K | |
| 80345 | <1% | 7,017 | $79K | |
| 80361 | <1% | 7,341 | $79K | |
| 80366 | <1% | 7,191 | $76K | |
| 80368 | <1% | 7,163 | $76K | |
| 80369 | <1% | 7,149 | $75K | |
| 80337 | <1% | 7,016 | $75K | |
| 80334 | <1% | 7,013 | $74K | |
| 99490 | Ccm add 20min | <1% | 3,887 | $63K |
| 80353 | <1% | 7,741 | $52K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,717 | $44K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,108 | $43K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 471 | $36K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 233 | $30K |
| 99408 | <1% | 3,015 | $30K | |
| 83992 | <1% | 7,753 | $29K | |
| 80358 | <1% | 7,574 | $28K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 398 | $24K |
| 80362 | <1% | 1,044 | $13K | |
| G2087 | Office-based treatment for opioid use disorder, including care coordination, individual therapy and group therapy and counseling; at least 60 minutes in a subsequent calendar month | <1% | 2,037 | $13K |
| 99443 | <1% | 153 | $12K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 587 | $10K |
| 99205 | Prolong outpt/office vis | <1% | 85 | $9K |
| 99407 | <1% | 545 | $9K | |
| T2022 | Case management, per month | <1% | 74 | $7K |
| 80324 | <1% | 535 | $6K | |
| 99439 | <1% | 346 | $5K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 334 | $1K |
| 90837 | Psychotherapy session, about an hour | <1% | 16 | $1K |
| 99442 | <1% | 23 | $864.24 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 275 | $836.86 |
| 36415 | Collection of venous blood by venipuncture | <1% | 594 | $756.39 |
| 80306 | <1% | 59 | $634.18 | |
| 96127 | <1% | 567 | $597.01 | |
| 96160 | <1% | 328 | $312.03 | |
| 80332 | <1% | 20 | $250.20 | |
| 80335 | <1% | 20 | $250.20 | |
| 80360 | <1% | 19 | $237.69 | |
| H0032 | Mental health service plan development by non-physician | <1% | 146 | $210.27 |
| G0443 | Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes | <1% | 28 | $79.64 |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 1,418 | $77.60 |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 0% | 69 | $0.00 |
| G9008 | Coordinated care fee, physician coordinated care oversight services | 0% | 55 | $0.00 |
| T1016 | Case management, each 15 minutes | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTACKLING, DANIEL (CFO)